Edition:
United States

Aralez Pharmaceuticals Inc (ARLZ.OQ)

ARLZ.OQ on NASDAQ Stock Exchange Global Select Market

0.05USD
16 Aug 2018
Change (% chg)

$-0.00 (-0.20%)
Prev Close
$0.05
Open
$0.05
Day's High
$0.05
Day's Low
$0.04
Volume
931,634
Avg. Vol
416,794
52-wk High
$2.98
52-wk Low
$0.04

Latest Key Developments (Source: Significant Developments)

Aralez Pharmaceuticals Posts Q4 Loss Per Share $0.68‍‍​
Tuesday, 13 Mar 2018 07:00am EDT 

March 13 (Reuters) - Aralez Pharmaceuticals Inc ::ARALEZ ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.‍TOTAL REVENUE FOR Q4 OF 2017 WERE $28.0 MILLION, AN INCREASE OF $8.0 MILLION, OR 40%, COMPARED TO $20.0 MILLION FOR SAME PERIOD OF 2016​.QTRLY LOSS PER SHARE $0.68‍​.‍2018 NET REVENUES TO BE IN A RANGE OF $140 MILLION TO $160 MILLION​.SEES ‍2018 ADJUSTED EBITDA TO BE IN A RANGE OF $35 MILLION TO $55 MILLION​.  Full Article

Aralez Announces Departure Of Chief Financial Officer
Thursday, 30 Nov 2017 05:00pm EST 

Nov 30 (Reuters) - Aralez Pharmaceuticals Inc ::ARALEZ ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.ARALEZ PHARMACEUTICALS INC - ‍SCOTT J. CHARLES, CHIEF FINANCIAL OFFICER, IS LEAVING COMPANY​.ARALEZ PHARMACEUTICALS INC - MICHAEL KASETA WILL ASSUME POSITION OF INTERIM CHIEF FINANCIAL OFFICER.ARALEZ PHARMACEUTICALS INC - ‍ PRIOR TO JOINING ARALEZ, KASETA SERVED AS CFO OF SANOFI NORTH AMERICA, GLOBAL SERVICES​.  Full Article

Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL
Wednesday, 29 Nov 2017 04:47pm EST 

Nov 29 (Reuters) - Lannett Company Inc ::LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®.LANNETT COMPANY INC - FINANCIAL TERMS WERE NOT DISCLOSED..LANNETT COMPANY INC - HAS ENTERED INTO AN AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC.LANNETT COMPANY - ‍AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF AUTHORIZED GENERIC VERSION OF TOPROL-XL​.LANNETT COMPANY INC - DEAL TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF TOPROL-XL EXTENDED RELEASE TABLETS IN 25 MG, 50 MG, 100 MG AND 200MG.  Full Article

Aralez Pharmaceuticals files for mixed shelf offering of up to $100 mln - SEC filing‍​
Thursday, 9 Nov 2017 05:30pm EST 

Nov 9 (Reuters) - Aralez Pharmaceuticals Inc :Aralez Pharmaceuticals Inc - files for mixed shelf offering of up to $100 million - SEC filing‍​.  Full Article

Aralez sees 2018 net revenues $140 mln to $160 mln‍​
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Aralez Pharmaceuticals Inc :Aralez announces third quarter 2017 financial results and achieves profitability on an adjusted EBITDA basis for the first time in the third quarter.Aralez Pharmaceuticals Inc - ‍provides updated 2017 full-year guidance and preliminary 2018 full-year outlook​.Aralez Pharmaceuticals Inc - ‍plans to implement further financial improvements designed to streamline U.S. business​.Aralez Pharmaceuticals Inc - ‍net loss in Q3 of 2017 was $24.4 million, or $0.37 per diluted share​.Qtrly total revenues, net $24.3 million versus $13.6 mln‍​.Aralez Pharmaceuticals Inc - ‍updated 2017 net revenues to be in a range of $95 million to $105 million​.Aralez Pharmaceuticals Inc - sees 2018 net revenues $140 million to $160 million‍​.  Full Article

Aralez qtrly loss per share ‍$0.42​
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Aralez Pharmaceuticals Inc ::Aralez reports second quarter 2017 financial results.Aralez Pharmaceuticals Inc - ‍total revenues for 3 months ended June 30, 2017 were $27.6 million compared to $12.6 million for three months ended June 30, 2016​.Qtrly loss per share ‍$0.42​.Aralez Pharmaceuticals Inc - ‍as of June 30, 2017 company had cash and cash equivalents of approximately $55.8 million​.Aralez Pharmaceuticals Inc - ‍company currently believes it has sufficient cash to fund operations for at least next 12 months​.  Full Article

Aralez Pharmaceuticals announces commercial launch of Zontivity
Wednesday, 7 Jun 2017 06:30am EDT 

June 7 (Reuters) - Aralez Pharmaceuticals Inc ::Aralez announces national U.S. commercial launch of Zontivity.Has also advanced its goal of ensuring patient access to Zontivity with an out-of-pocket cost competitive to other branded anti-platelet agents.Aralez Pharmaceuticals Inc says national commercial launch of Zontivity in U.S. will commence this week.  Full Article

Aralez Pharmaceuticals Q1 loss per share of $0.42
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Aralez Pharmaceuticals Inc :Aralez reports first quarter 2017 financial results.Qtrly loss per share of $0.42 per share.Qtrly net total revenues $26 million versus $8.1 million.  Full Article

Aralez Pharma says co and U.S. Government entered into modification of contract
Tuesday, 11 Apr 2017 04:30pm EDT 

Aralez Pharmaceuticals Inc : Aralez Pharma - on April 6, aralez us and u.s. government entered into modification of contract under which government exercised first renewal option under deal .Aralez Pharmaceuticals Inc - U.S. Government extended term of agreement by one year to April 28, 2018 with modified pricing for duration thereof.  Full Article

Aralez reports reduction in U.S. sales force
Wednesday, 5 Apr 2017 06:30am EDT 

Aralez Pharmaceuticals Inc : Aralez announces reduction in U.S. Sales force and cost savings program . Aralez Pharmaceuticals Inc - 32 pct reduction in U.S. sales force . Aralez Pharmaceuticals Inc - reduction in sales force is expected to reduce current annual run rate of operating expenses by approximately $7.5 million . Aralez Pharmaceuticals Inc - sales force restructuring is expected to yield savings for 2017 and beyond . Aralez Pharmaceuticals Inc - strategic realignment of resources with an emphasis on zontivity launch . Aralez Pharmaceuticals says as a result of sales force reduction, anticipates it will incur cash severance costs of approximately $0.6 million in q2 of 2017 . Aralez Pharmaceuticals Inc - company intends to communicate details of the plan in its q1 2017 earnings release to be issued in early may 2017 . Aralez Pharma- plan includes realignment of certain financial resources to support phased launch of zontivity that is expected to begin in mid-april . Aralez Pharmaceuticals Inc says is in process of finalizing its overall cost savings plan . Aralez Pharmaceuticals Inc - cost savings plan includes significant decrease in marketing spend on yosprala .Aralez Pharma-has begun other initiatives expected to reduce spending across business, some of which were already assumed in previously issued financial guidance.  Full Article

BRIEF-Aralez Pharmaceuticals Announces Discontinuation Of U.S. Commercial Operations, With Reductions In Operating Expenses

* ARALEZ PHARMACEUTICALS INC - DISCONTINUATION OF U.S. COMMERCIAL OPERATIONS, WITH SIGNIFICANT REDUCTIONS IN OPERATING EXPENSES